Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Address
8 rue de la Croix-Jarry, Paris 13
PARIS, 75013
France
PARIS, 75013
France
Website
http://www.cellectis.comKey stats and ratios
| Q2 (Jun '17) | 2016 | |
| Net profit margin | -295.53% | -119.15% |
| Operating margin | -221.35% | -119.23% |
| EBITD margin | - | -115.32% |
| Return on average assets | -32.27% | -18.54% |
| Return on average equity | -39.32% | -23.30% |
| Employees | 89 |
No comments:
Post a Comment